论文部分内容阅读
两种新的血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂已获美国FDA批准上市,依非巴肽(eptifibatide,商品名Integrilin)准可用于治疗急性冠脉综合征(不稳定心绞痛或无Q波的心肌梗死)或经皮冠脉介入[血管成形术和粥样硬化切除术(atherectomy)]。替罗非班(tirofiban,商品名Aggrastat)准可
Two new platelet glycoprotein IIb / IIIa receptor antagonists have been approved by the US FDA for marketing. Eptifibatide (trade name Integrilin) is expected to be used for the treatment of acute coronary syndromes (unstable angina or Q wave-free Myocardial infarction) or percutaneous coronary intervention [angioplasty and atherectomy]. Tirofiban (trade name Aggrastat) is permitted